KalVista Pharmaceuticals Aktie
WKN DE: A2DG49 / ISIN: US4834971032
25.07.2025 14:31:17
|
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat
(RTTNews) - KalVista Pharmaceuticals (KALV) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for sebetralstat, an oral plasma kallikrein inhibitor, for symptomatic treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older. The European Commission final decision is expected by early October.
Sebetralstat is approved in the United States and United Kingdom under the brand name EKTERLY for the treatment of hereditary angioedema attacks in people 12 years of age and older.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu KalVista Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu KalVista Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
KalVista Pharmaceuticals Inc | 9,95 | 0,00% |
|